Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer

Pinato, David J.; Ferrante, Daniela; Aguilar-Company, Juan; Bower, Mark; Salazar, Ramón; Mirallas, Oriol; Sureda, Anna; Bertuzzi, Alexia; Brunet, Joan; Lambertini, Matteo; Maluquer, Clara; Pedrazzoli, Paolo; Biello, Federica; Lee, Alvin; Sng, Christopher C.T.; Liñan, Raquel; Rossi, Sabrina; Carmona-García, Maria Carmen; Sharkey, Rachel; Eremiev, Simeon; Rizzo, Gianpiero; Bain, Hamish DC; Yu, Tamara; Cruz, Claudia Andrea; Perachino, Marta; Saoudi-Gonzalez, Nadia; Fort-Culillas, Roser; Doonga, Kris; Fox, Laura; Roldán, Elisa; Zoratto, Federica; Gaïdano, Gianluca; Ruiz‐Camps, Isabel; Bruna, Riccardo; Patriarca, Andrea; Shawe-Taylor, Marianne; Fusco, Vittorio; Martínez-Vila, Clara; Berardi, Rossana; Filetti, Marco; Mazzoni, Francesca; Santoro, Armando; Delfanti, Sara; Parisi, Alessandro; Queirolo, Paola; Aujayeb, Avinash; Rimassa, Lorenza; Prat, Aleix; Tabernero, Josep; Gennari, Alessandra; Cortellini, Alessio

doi:10.1016/j.ejca.2022.04.036

Cited by 22 publications

(14 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, recent reports regarding the continued susceptibility of unvaccinated cancer patients to SARS-CoV-2 have highlighted the importance of vaccination in this patient group. [14] , [15] …”

mentioning

confidence: 99%

2022 update on the clinical outcome of coronavirus disease 2019 in haemato-oncology patients

et al. 2022

View full text Add to dashboard Cite

mentioning

confidence: 99%

2022 update on the clinical outcome of coronavirus disease 2019 in haemato-oncology patients

et al. 2022

View full text Add to dashboard Cite

“…There were a difference mortality rates at 14 and 28 day between fully vaccinated and unvaccinated patients, respectively 5.5% vs 20.7% (P = 0.0004) and 13.2% vs 27.4%, (P = 0.0028). Fully vaccinated patients had fewer sequelae than unvaccinated patients (6.7% vs 17.2%, P = 0.0320) (19). This suggests that seroconversion and presumably serological level must in uence COVID-19 morbidity and mortality in cancer and reinforces the need to verify the speci c immune response by monitoring this response by adapting the strategy on a personalized basis.…”

Section: Discussionmentioning

confidence: 87%

“…This suggests that seroconversion and presumably serological level must in uence COVID-19 morbidity and mortality in cancer and reinforces the need to verify the speci c immune response by monitoring this response by adapting the strategy on a personalized basis. In addition to the threat posed by acute morbidity and mortality from COVID-19 in cancer patients, recent evidence highlights that the continuity of oncology care may be further disrupted by the long-term consequences of COVID-19, which affect approximately 15% of cancer patients recovering from the acute phase (19). Recommendations for vaccination were made for elderly people with systematic vaccination every 6 months with no serological monitoring (20).…”

Section: Discussionmentioning

confidence: 99%

Real-world data on bio-clinical follow-up after vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in 216 patients with hematological malignancies

Rossi

Bonnet

Castelli

et al. 2022

Preprint

View full text Add to dashboard Cite

Hematological malignancies patients (HM) have heterogeneous serological response after vaccination. Real-world data. 216 patients with HM and 12 non-malignant hemopathies received BNT162b2 COVID-19 and monitored for >1 year. The first 43 patients had initial follow-up by telemedicine system (TM). Anti-Spike IgG antibodies were monitored 3-4 weeks post-1st vaccination and every 3-4 months, by 2 standard bioassays and a rapid serological test (RST). Vaccine boosts were given when the level was <7BAU/mL. Patients who did not seroconvert after 3-4 doses received tixagevimab/cilgavimab (TC). Follow-up and results. Tolerance using TM was good. 15 results were discordant between 2 standard bioassays. Good agreement was observed between standard and RST on 97 samples. After 2 doses, 68% were seroconverted (median 59 BAU/mL) with a median of 162 BAU/mL in untreated patients and 9 BAU/mL in treated patients (P<0.001), particularly for patients receiving rituximab. Patients with low levels of gammaglobulin levels (<5g/L) had reduced seroconversion (p=0.019). Median levels were 228 BAU/mL post-2nd dose if seroconverted post-1st and 2, if seronconverted only post-2nd. 68% of post-2nd negative patients were post-3rd positive. 16 pts received TC, 6 with non-severe symptomatic COVID-19 within 15-40 days. Conclusion: Personalized serological monitoring must be applicated particularly for HM patients.

show abstract

“…This suggests that seroconversion and presumably serological level must influence COVID-19 morbidity and mortality in cancer and reinforces the need to verify the specific immune response by monitoring this response by adapting the strategy on a personalized basis. In addition to the threat posed by acute morbidity and mortality due to COVID-19 in cancer patients, recent evidence highlights that the continuity of oncology care may be further disrupted by the long-term consequences of COVID-19, which affect approximately 15% of cancer patients recovering from the acute phase [ 23 ]. Vaccination recommendations have been made for the elderly with routine vaccinations every 6 months without serological monitoring [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study

et al. 2023

View full text Add to dashboard Cite

Hematological malignancies (HMs) have heterogeneous serological responses after vaccination due to disease or treatment. The aim of this real-world study was to analyze it after Pfizer-BioNT162b2 mRNA vaccination in 216 patients followed up for 1 year. The first 43 patients had an initial follow-up by a telemedicine (TM) system with no major events reported. The anti-spike IgG antibodies were checked 3–4 weeks post-first vaccination and every 3–4 months, by two standard bioassays and a rapid serological test (RST). Vaccine boosts were given when the level was <7 BAU/mL. Patients who did not seroconvert after 3–4 doses received tixagevimab/cilgavimab (TC). Fifteen results were discordant between two standard bioassays. Good agreement was observed between the standard and RST in 97 samples. After two doses, 68% were seroconverted (median = 59 BAU/mL) with a median of 162 BAU/mL and 9 BAU/mL, respectively, in untreated and treated patients (p < 0.001), particularly for patients receiving rituximab. Patients with gammaglobulin levels < 5 g/L had reduced seroconversion compared to higher levels (p = 0.019). The median levels were 228 BAU/mL post-second dose if seroconverted post-first and second, or if seroconverted only post-second dose. A total of 68% of post-second dose negative patients were post-third dose positive. A total of 16% received TC, six with non-severe symptomatic COVID-19 within 15–40 days. Personalized serological follow-up should apply particularly to patients with HMs.

show abstract

Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer

Cited by 22 publications

References 33 publications

2022 update on the clinical outcome of coronavirus disease 2019 in haemato-oncology patients

2022 update on the clinical outcome of coronavirus disease 2019 in haemato-oncology patients

Real-world data on bio-clinical follow-up after vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in 216 patients with hematological malignancies

Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study

Contact Info

Product

Resources

About